Researchers at the University of South Florida have focused on the demyelination hallmark of traumatic brain injury (TBI) and have tested a liver X receptor (LXR) agonist, GW-3965, for the potential treatment of it. Activation of LXRs is known to support oligodendrocyte maturation, increase myelin gene expression and promote remyelination.